Replimune Group Inc

Replimune’s new stock option grant signals confidence in its oncolytic cancer therapy pipeline and may boost investor confidence ahead of key FDA approvals.

Replimune insider deals reveal tax‑efficient RSU sales paired with cashless ESO exercises, underscoring executive confidence amid promising oncolytic immunotherapy prospects.

Insider buying spurs confidence in Replimune’s oncolytic therapy pipeline, with Astley‑Sparke Philip’s purchase and options showing long‑term conviction for investors.

RPGC insider buying surge signals confidence in oncolytic therapy growth – insiders grab options below market price, hinting at future upside and potential dilution.

Replimune’s 6,500‑share Rule 10b5‑1 sale by its COO is routine, but the move comes just before its FDA review of RP1, a potential game‑changer for oncology investors. Read how insider activity and regulatory milestones could shape the company’s futu…